Compare McCormick & Company, Incorporated (MKC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Zimmer Biomet Holdings Inc — how do they compare? McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and McCormick & Company, Incorporated pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| MKC | ZBH | |
|---|---|---|
Market Cap | $14.04B | $17.36B |
Sector | Consumer Staples | Health |
52-Week High | $72.81 | $107.71 |
52-Week Low | $45.60 | $79.58 |
Enterprise Value | $18.65B | $24.40B |
Dividend Yield | 3.68% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $52.35, up 1.26% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 21.91% net margin and 25.7% ROE, supported by recent Q2 2026 earnings beating estimates. Valuation appears attractive with a P/E of 8.69 and P/S of 1.9. The pending Unilever Foods deal, highlighted in recent news (The Motley Fool, 2026-07-07), could transform the business, though organic growth remains modest.
The outlook is cautiously optimistic with 36.7% of analysts rating it Buy and a consensus price target of $59.67 (13.9% upside). Key risks include soft consumer volumes and execution challenges from the Unilever integration. Positive cash flow projections for 2026 and a sustainable dividend enhance appeal, but investors should monitor volume trends and deal progress closely.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
